Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v15-FR | Version v5-FR | |
---|---|---|
Language | French | French |
Date Updated | 2024-04-11 | 2023-11-24 |
Drug Identification Number | 02488930 | 02488930 |
Brand name | BUPIVACAINE HYDROCHLORIDE INJECTION, USP | BUPIVACAINE HYDROCHLORIDE INJECTION, USP |
Common or Proper name | Bupivacaine Hydrochloride | Bupivacaine Hydrochloride |
Company Name | BAXTER CORPORATION | BAXTER CORPORATION |
Ingredients | BUPIVACAINE HYDROCHLORIDE | BUPIVACAINE HYDROCHLORIDE |
Strength(s) | 7.5MG | 7.5MG |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | RETROBULBAR EPIDURAL | RETROBULBAR EPIDURAL |
Packaging size | AIN03056 | AIN03056 |
ATC code | N01BB | N01BB |
ATC description | ANESTHETICS, LOCAL | ANESTHETICS, LOCAL |
Reason for shortage | Requirements related to complying with good manufacturing practices. | Requirements related to complying with good manufacturing practices. |
Anticipated start date | 2024-04-12 | 2023-11-16 |
Actual start date | 2023-11-16 | |
Estimated end date | Unknown | |
Actual end date | 2024-04-11 | |
Shortage status | Avoided shortage | Actual shortage |
Tier 3 Status | Yes | No |
Company comments | Product remains available. Baxter continues to work to mitigate any potential supply risk. Contact your Baxter Pharmacy representative for additional information. | |
Health Canada comments |